Finally, the CLK1-specific inhibitor, CTX-712, is in Phase 1/2 trial for relapsed or refractory AML and high risk MDS47, underscoring CLK1 and its family as a target across diverse tumor histologies. Here, CLK1 is linked to neoplasm.